Treatment of pre‐menopausal advanced breast cancer with goserelin—a long‐acting luteinizing hormone releasing hormone agonist

@article{Brambilla1992TreatmentOP,
  title={Treatment of pre‐menopausal advanced breast cancer with goserelin—a long‐acting luteinizing hormone releasing hormone agonist},
  author={C. Brambilla and A. Escobedo and R. Artioli and M. Lechuga and M. Motta},
  journal={Anti-Cancer Drugs},
  year={1992},
  volume={3},
  pages={3–8}
}
  • C. Brambilla, A. Escobedo, +2 authors M. Motta
  • Published 1992
  • Medicine
  • Anti-Cancer Drugs
  • Twenty-two pre-menopausal evaluable patients with advanced breast cancer (median age 39 years; ER positive 19, unknown three; prior adjuvant chemotherapy 16) were treated with the LHRH agonist goserelin depot (Zoladex*). Serum levels of 17 β-estradiol and progesterone were suppressed by goserelin within 3–4 weeks of therapy, while serum leuteinizing hormone and follicle stimulating hormone titers remained in the low level of the normal range. Complete or partial response was documented in seven… CONTINUE READING
    10 Citations
    LHRH agonist treatment of breast cancer and gynecological malignancies: a review.
    • 19
    Clinical Pharmacokinetics of Goserelin
    • 41
    Hormonal therapy for breast cancer. An update.
    • 22
    Endocrinology of Breast Cancer
    • A. Manni
    • Medicine
    • Contemporary Endocrinology
    • 1999
    • 4